NASDAQ:CLDX

Celldex Therapeutics Stock Signals

etoro logo Buy CLDX
*Your capital is at risk
$26.00
+0.450 (+1.76%)
At Close: Nov 17, 2025

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 2.087 1 day ( 0 % )
Last Price $26.00 1.76 %
High/ Low $25.46 - $26.50 15.20%
Chg 7 Days 14.69 % $22.67 $26.00
Chg 30 Days -3.09 % $26.83 $26.00
Chg 12 mos 10.40 % $23.55 $26.00
Trend - 3 mos 11.69 % Width: 25.76 %
Trend - 12 mos 3.17 % Width: 78.63 %
Pred. range - 3 mos $25.58 - $32.17 -1.61 % - 23.74 %
Pred. range - 12 mos $16.16 - $28.86 -37.86 % - 11.01 %
Short MA avg 3 mos Buy Nov 10, 2025 - 6 days
Long MA avg 3 mos Buy Nov 14, 2025 - 2 days
Short/Long MA avg 3 mos Sell Nov 03, 2025 - 11 days
Short MA avg 12 mos Buy Nov 13, 2025 - 3 days
Long MA avg 12 mos Sell Nov 12, 2025 - 4 days
Short/Long MA avg 12 mos Buy Jun 20, 2025 - 105 days
Pivot Short Sell Nov 10, 2025 - 6 days
Bollinger Buy Nov 07, 2025 - 7 days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!
ABOUT CELLDEX THERAPEUTICS
Celldex Therapeutics
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity...
GOLDEN STAR
Ticker Change Signal Date
UNIT
$6.00
4.83% Nov 04
TBPH
$14.14
27.58% Oct 23
A
AMIX
$1.12
2.68% Oct 23
COCO
$40.85
11.21% Oct 23
LAUR
$29.55
1.20% Oct 22

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE